(Reuters) – Drugmaker Incyte said on Tuesday its cream to treat a type of skin disease met its main goal of improving skin clarity in patients with atopic dermatitis in a late-stage study.
Atopic dermatitis is a common chronic disease characterized by inflammation of the skin.
The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.
Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel
Our Standards:The Thomson Reuters Trust Principles.
